^
    4years
    Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    IT MEDI9197 was feasible for subcutaneous/cutaneous lesions but AEs precluded its use in deep-seated lesions. Although no patients responded, MEDI9197 induced systemic and intratumoral immune activation, indicating potential value in combination regimens in other patient populations.
    Clinical • Journal • Combination therapy • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Imfinzi (durvalumab) • telratolimod (MEDI9197)
    4years
    Intratumoral administration of the Toll-like receptor 7/8 agonist 3M-052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. (PubMed, Clin Transl Immunology)
    3M-052 action was demonstrated via dendritic cell activation and production of type I IFN and other pro-inflammatory cytokines to initiate a T-cell-inflamed TME and promote tumor cell antigen presentation. This work supports neoadjuvant TLR agonist-based immunotherapeutics as realistic options for immune activation in the TME and long-term metastatic protection in TNBC.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    telratolimod (MEDI9197)
    almost5years
    Intratumoral administration of a type I IFN-inducer promotes tumor immunogenicity and metastatic suppression in preclinical TNBC (LCC 2020)
    3M-052 action was IFN-dependent, via DC activation and production of IFN and other pro-inflammatory cytokines to initiate a T cell-inflamed tissue microenvironment (TME) and promote tumor antigen presentation. Our results indicate that a single intratumoral treatment can induce TME immunoreactivity that is capable of inducing long-term protection from metastasis through formation of immunological memory and suggests that trialling IFN inducers in TNBC patients is warranted.
    Preclinical
    |
    CD8 (cluster of differentiation 8)
    |
    telratolimod (MEDI9197)